Price movement over the last 24 hours
Adecoagro SA vs 10X Genomics Inc — how do they compare? Adecoagro SA trades at $10.17 (market cap $1.39B), while 10X Genomics Inc trades at $36.31 (market cap $4.80B). The key difference: 10X Genomics Inc is far larger — about 3.5× Adecoagro SA's market cap, and Adecoagro SA pays a 3.08% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| AGRO | TXG | |
|---|---|---|
Market Cap | $1.39B | $4.80B |
Sector | Technology | Health |
52-Week High | $15.25 | $40.00 |
52-Week Low | $7.13 | $11.34 |
Enterprise Value | $3.42B | $4.35B |
Dividend Yield | 3.08% | — |
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.48, down 1.66% today, with a bearish technical signal despite neutral oscillators. The company reported mixed quarterly results, missing Q1 2026 EPS estimates but showing strong adjusted EBITDA growth. Valuation metrics appear attractive with P/S of 0.71 and P/B of 0.78, though profitability remains weak with a 0.91% net margin. Recent news highlights innovation in agriculture operations and a declared $0.12 dividend for H1 2026.
The stock offers value appeal with below-market multiples and analyst consensus target of $12.75 implying 34% upside. However, inconsistent earnings performance and negative net income in 2025 pose execution risks. The bearish technical trend and competitive pressures in sustainable agriculture require careful monitoring for potential investors.
TXG trades at $37.83, down 3.02% today, with a bullish technical setup despite recent weakness. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining strong 69.6% gross margins. Recent collaborations with Cleveland Clinic and the Proteintech acquisition enhance its multiomics capabilities. Technical indicators show strong momentum with the price above key moving averages, though RSI levels suggest potential overbought conditions near-term.
The outlook remains cautiously optimistic as TXG progresses toward profitability, with analyst consensus at $31.00 representing 18% downside risk. Key opportunities include expanding diagnostic applications and platform adoption, while risks center on continued losses, high valuation multiples, and competitive pressure in life sciences technology.
Trailing returns across standard periods
Latest headlines on both assets
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →